KPC Pharmaceuticals,Inc.

SHSE:600422 株式レポート

時価総額:CN¥11.5b

KPC PharmaceuticalsInc 過去の業績

過去 基準チェック /46

KPC PharmaceuticalsInc's earnings have been declining at an average annual rate of -2.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 0.8% per year. KPC PharmaceuticalsInc's return on equity is 7.9%, and it has net margins of 5.9%.

主要情報

-2.4%

収益成長率

-2.1%

EPS成長率

Pharmaceuticals 業界の成長10.9%
収益成長率-0.8%
株主資本利益率7.9%
ネット・マージン5.9%
前回の決算情報30 Sep 2024

最近の業績更新

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Mar 28
KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Recent updates

Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

Sep 30
Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

Sep 11
These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Jul 25
KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

Jun 25
Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

Jun 04
We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Mar 28
KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

収支内訳

KPC PharmaceuticalsInc の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

SHSE:600422 収益、費用、利益 ( )CNY Millions
日付収益収益G+A経費研究開発費
30 Sep 247,5504462,47488
30 Jun 247,4874512,57579
31 Mar 247,6464322,70572
31 Dec 237,7034452,79171
30 Sep 237,7003972,73739
30 Jun 237,8253902,81546
31 Mar 237,8284002,85257
31 Dec 228,2823832,85170
30 Sep 228,4194462,865102
30 Jun 228,3883922,825108
31 Mar 228,7224272,821104
31 Dec 218,2545082,815101
30 Sep 218,3215402,806140
30 Jun 218,3865642,874139
31 Mar 218,0455602,834145
01 Jan 217,7174572,672128
30 Sep 207,7794452,952103
30 Jun 207,7884442,99093
31 Mar 207,9104433,09479
31 Dec 198,1204543,33784
30 Sep 197,8174293,22677
30 Jun 197,4733903,15983
31 Mar 197,2373563,06277
31 Dec 187,1023363,00083
30 Sep 186,7973162,84270
30 Jun 186,5072952,64190
31 Mar 186,2803182,37983
31 Dec 175,8523302,13063
30 Sep 175,6373571,93640
30 Jun 175,3303741,7460
31 Mar 175,1704161,6180
31 Dec 165,1014071,5190
30 Sep 165,1614401,2950
30 Jun 165,2274481,3040
31 Mar 165,0494331,2240
31 Dec 154,9164211,1770
30 Sep 154,5884041,0760
30 Jun 154,4563679830
31 Mar 154,3613089900
31 Dec 144,3162899310
30 Sep 144,0382649040
30 Jun 143,8602588300
31 Mar 143,6682437250
31 Dec 133,5842327280

質の高い収益: 600422 has high quality earnings.

利益率の向上: 600422's current net profit margins (5.9%) are higher than last year (5.1%).


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: 600422's earnings have declined by 2.4% per year over the past 5 years.

成長の加速: 600422's earnings growth over the past year (12.5%) exceeds its 5-year average (-2.4% per year).

収益対業界: 600422 earnings growth over the past year (12.5%) exceeded the Pharmaceuticals industry -1.2%.


株主資本利益率

高いROE: 600422's Return on Equity (7.9%) is considered low.


総資産利益率


使用総資本利益率


過去の好業績企業の発掘